futibatinib - Shore News Network

Taiho Oncology Announces Updated Efficacy and Safety Data for Futibatinib in Cholangiocarcinoma at 2022 ASCO Annual Meeting

Your NewsJune 4, 20220116 views

These data are part of a New Drug Application that has been granted priority review by the U.S. Food and Drug Administration PRINCETON, N.J., June 3, 2022 — Taiho Oncology,…

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Taiho Oncology’s New Drug Application for Futibatinib for Cholangiocarcinoma

Your NewsMarch 30, 20220126 views

Each year, approximately 8,000 individuals in the U.S. are diagnosed with CCA,1 a rare cancer of the bile ducts of the liver, and approximately 0.3-6 people per 100,000 individuals live…